Intz lal Appilcation No INTERNATIONAL SEARCH REPORT PCT/EP 00/05318 C. (Continuatlon) DOCUMENTS CONSIDERED TO BE RELEVANT Category ! Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No. X FRIDELL YIH-WOEI C ET AL:"GAS6 induces 5,6,8,9 Axl-mediated chemotaxis of vascular smooth muscle cells." JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 273, no. 12, 20 March 1998 (1998-03-20), pages 7123-7126, XP002154999 ISSN:0021-9258 cited in the application page 7125, right-hand column page 7126, right-hand column abstract X NAKANO TORU ET AL:"Requirement of 5,7,10 gamma-carboxyglutamic acid residues for the biological activity of Gas6: Contribution of endogenous Gas6 to the proliferation of vascular smooth muscle cells." BIOCHEMICAL JOURNAL, vol. 323, no. 2,1997, pages 387-392, XP002155000 ISSN: 0264-6021 cited in the application page 389, right-hand column, paragraph 1 page 390, right-hand column, paragraph 3 X O'DONNELL KRISTY ET AL:"Expression of 5,7-9 receptor tyrosine kinase Axl and its ligand Gas6 in rheumatoid arthritis: Evidence for a novel endothelial cell survival pathway." AMERICAN JOURNAL OF PATHOLOGY, vol. 154, no. 4, April 1999 (1999-04), pages 1171-1180, XP000971169 ISSN: 0002-9440 abstract; figure 5 FURTHER INFORMATION CONTINUED FROM PCT/ISAI 210 This International Searching Authority found multiple (groups of) inventions in this international application, as follows: 1. Claims: 1-4 Non-human transgenic animal deficient in Gas6 function and its use. 2. Claims: 10; in part: 5-7 Use of an inhibitor of the Gas6 function for the manufacture of a medicament. 3. Claims: 8,9; in part: 5-7 Use of an inhibitor of a Gas6 receptor for the manufacture of a medicament. FURTHER INFORMATION CONTINUED FROM PCT/ISA/210 Continuation of Box 1. 2 Claims Nos.: in part: 5-8 Claims 5-8 refer to an inhibitor of the Gas6 function and/or an inhibitor of a Gas6 receptor without giving a true technical characterization. Moreover, no such specific inhibitors are defined in the application. In consequence, the scope of said claims is ambiguous and vague, and its subject-matter is not sufficiently disclosed and supported (Art. 5 and 6 PCT). No complete search can be carried out for such purely speculative claims whose wording is, in fact, a mere recitation of the result to be achieved. Therefore, the search was limited to inhibitors which are either a soluble form of the AXL, MER or RSE receptor or a Gas6 antibody. The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1 (e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure. INTERNATIONAL SEARCH REPORT lnte I Application No Intormanon on patenttamuy members PCT/EP 00/05318 Patent document Publication Patent family Publication cited in search report date member (s) date JP 11000079 A 06-01-1999 NONE JP 11000079 A 06-01-1999 NONE